Defining the Analytical Scope for Integrating Vectors

Lentiviral vectors require a specific preclinical safety evaluation due to their characteristic integration into the host cell genome. Regulatory authorities in Germany and across the EU mandate a clear understanding of not only where the vector distributes but also the genomic context of its integration. This necessitates two parallel, yet interconnected, analytical workstreams: biodistribution quantification and genomic integration site mapping.

Our approach isolates and analyzes vector presence and activity through multiple validated methods:

• Vector Copy Number (VCN): Quantifies the amount of vector DNA per cell in various tissues using qPCR or ddPCR.

• Transgene Expression: Measures the level of therapeutic transgene mRNA using RT-qPCR to confirm biological activity.

• Genomic Integration Profiling: Identifies the specific locations of vector integration within the host genome to evaluate safety.

Quantitative Biodistribution: Tracking Vector Fate and Function

A primary objective of the preclinical program is to build a comprehensive map of vector localization and persistence. This level of quantification provides high-fidelity intelligence tracking therapeutic delivery across all relevant biological compartments. We design studies to assess vector kinetics over time, providing a clear picture of vector clearance from non-target tissues and stable persistence in target cells.

Sustained transgene expression is a key indicator of therapeutic potential. As demonstrated in studies of lentiviral-mediated gene transfer, achieving long-term expression in the intended tissues is a primary goal for durable efficacy (PMID: 12778376). Our assays are designed to confirm not just the presence of the vector but its functional consequence: stable expression of the therapeutic payload.

Watch the full “DIVERSIFYING THE VALUE CHAIN” video

Integration Site Analysis: A Mandated Genomic Safety Assessment

While biodistribution confirms if a vector reached a tissue, ISA answers what it does upon arrival at the genomic level. This analysis is a direct measure of genotoxic risk. The potential for vector integration near oncogenes or gene regulatory elements is a known risk that must be thoroughly investigated.

Precedent from other vector systems reinforces the need for this scrutiny. Studies have shown that viral vector integration is not always random and can occur in specific genomic loci, a finding that warrants careful monitoring in human trials (PMID: 23621841). By mapping integration sites using methods like LAM-PCR or advanced NGS platforms, we can identify integration hotspots and assess any potential for clonal expansion or dysregulation of endogenous genes.